Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab in HER2-negative Gastric Cancer with HER2+ CTCs
NCT04168931Phase 2Terminated
- Sponsor
- A.C.Camargo Cancer Center
- Start
- Jan 2020
- Primary completion
- Jan 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab in gastric cancer (GC), sponsored by A.C.Camargo Cancer Center. Started Jan 2020; status: terminated.
02
Drugs
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT04168931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04168931.